Palonosetron

Palonosetron

SCHEMBL3746

O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

HTR3A

The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR3A known ✓ P46098 10/20 1.00
HTR3B O95264 1/20 1.00
ADRA2A P08913 1/20 1.00
KCNE1 P15382 1/20 1.00
ADRA2C P18825 1/20 1.00
CHRM3 P20309 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
HRH1 P35367 1/20 1.00
DRD3 P35462 1/20 1.00
CHRNA4 P43681 1/20 1.00
KCNQ1 P51787 1/20 1.00
KCNH2 Q12809 1/20 1.00
SCN5A Q14524 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Palonosetron SCHEMBL29402278 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL4058558 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL2989775 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL7782594 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL7277880 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL10066801 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL3748 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL13240607 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL4052980 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C
Palonosetron SCHEMBL3747 1.00 HTR3A (1.00) HTR3AHTR3BADRA2AKCNE1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 11151 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144776-A1 COMBINATION THERAPY FOR A DOPAMINE AGONIST ALTO NEUROSCIENCE, INC. (US) 2026-05-28 US claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
US-20260130929-A1 USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) 2026-05-14 US claimed
WO-2026090164-A1 COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN KALLYOPE, INC. (US) 2026-04-30 WO claimed
EP-4727627-A1 AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW Alexza Pharmaceuticals, Inc. (US) 2026-04-22 EP claimed
EP-4725483-A1 COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE Université de Bordeaux (FR) 2026-04-15 EP claimed
US-20260097042-A1 COMPOUND EMULSION, PREPARATION METHOD THEREFOR, AND USE THEREOF QILU PHARMACEUTICAL CO LTD (CN) 2026-04-09 US claimed
EP-4719552-A1 INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP claimed
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
US-20260069687-A1 THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER ASTELLAS PHARMA INC (JP) 2026-03-12 US claimed
WO-2002036114-A1 COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 RESPIRATORIUS AB (SE) 2002-05-10 WO claimed
WO-2002036113-A1 COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) RESPIRATORIUS AB (SE) 2002-05-10 WO claimed
WO-2001095902-A9 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS 2002-04-25 WO claimed
EP-1185263-A2 RECEPTOR AGONISTS AND ANTAGONISTS Respiratorius AB (SE) 2002-03-13 EP claimed
WO-2001095902-A1 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS RESPIRATORIUS AB (SE) 2001-12-20 WO claimed
WO-2001095903-A1 5-HT3 RECEPTOR ANTAGONISTS FOR TREATMENT OF DISORDERS INVOLVING AIRWAY CONSTRICTION RESPIRATORIUS AB (SE) 2001-12-20 WO claimed
EP-0770077-B1 PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT HOFFMANN LA ROCHE (CH) 2001-09-19 EP claimed
WO-2000076500-A2 COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION RESPIRATORIUS AB (SE) 2000-12-21 WO claimed
US-5567818-A Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein SYNTEX (U.S.A.) INC. (US) 1996-10-22 US claimed
US-5202333-A Tricyclic 5-HT3 receptor antagonists SYNTEX (U.S.A.) INC. (US) 1993-04-13 US claimed